Main container

Milena Fini Scientific Director

Former director of a Rizzoli research laboratory, she will take office on 1 July

June 22nd, 2022
Foto della Dr.ssa Milena Fini, nuova direttrice scientifica dell'IRCCS Istituto Ortopedico Rizzoli
Milena Fini, new scientific director of the IRCCS Rizzoli Orthopaedic Institute 

Milena Fini is the new Scientific Director of the Rizzoli Orthopaedic Institute in Bologna, appointed by the Minister of Health after consultation with the President of the Emilia-Romagna Region.

Director of the Surgical Sciences and Technologies Unit at the Rizzoli, Fini carries out activities at an international level on technological innovations and new therapeutic strategies in the musculoskeletal field. She is co-responsible for the translational research line "Regenerative and Restorative Medicine" and participates in the projects of the national IRCCS networks dealing with regeneration and reconstruction of the musculoskeletal system and ageing.

She has been active in the study of traumatic, degenerative, infectious and oncological musculoskeletal diseases and in projects and clinical studies carried out in collaboration with the Rizzoli orthopaedic departments. In addition, Fini, who will take up her post as scientific director on 1 July, has developed research of international weight on biomaterials, osteoporosis and osteoarthritis, spinal and prosthetic surgery, fractures and loss of tissue substance.

Attachments

Contacts

You might also be interested in

Foto con paziente intervento tumore primitivo Bagheria
Thirteen year old girl from Palermo operated on her back at Rizzoli in Bagheria
Primary bone cancer removed. The surgery was performed in collaboration with the Palermo Civic Hospital
La D.ssa Rizzo e la D.ssa Gaziano, fisiatre del Dipartimento Rizzoli-Sicilia
Physiatric clinic specialised in childhood motor disabilities has started
Specialist visits on orthopaedic pathologies are available every Monday
Un momento della firma dell'accordo
The collaboration between University of Catania and Rizzoli has started
Research activities about biomaterials, medical devices, preclinical models and in-silico medicine will be made